<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127911">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02106975</url>
  </required_header>
  <id_info>
    <org_study_id>HM20000917</org_study_id>
    <secondary_id>1UM1HL116885-01</secondary_id>
    <nct_id>NCT02106975</nct_id>
  </id_info>
  <brief_title>Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury</brief_title>
  <acronym>CITRIS-ALI</acronym>
  <official_title>Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis 1A: Vitamin C infusion will significantly attenuate sepsis-induced systemic organ
      failure as measured by Sequential Organ Failure Assessment (SOFA) score,

      Hypothesis 1B: Vitamin C infusion will attenuate sepsis-induced lung injury as assessed by
      the oxygenation index and the VE40

      Hypothesis 1C: Vitamin C infusion will attenuate biomarkers of inflammation (C-Reactive
      Protein, Procalcitonin), vascular injury (Thrombomodulin, Angiopoietin-2), alveolar
      epithelial injury (Receptor for Advanced Glycation Products), while inducing the onset of a
      fibrinolytic state (Tissue Factor Pathway Inhibitor).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in SOFA score at 96 hours as compared to baseline when compared to placebo</measure>
    <time_frame>96 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>C-Reactive Protein and Thrombomodulin at study hours 0, 48, 96, 168 when compared to placebo</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygenation Index (FiO2 x Mean Airway Pressure/PaO2) at study hour 0, 48, 96, 168 if still intubated in ascorbate infused patient compared to placebo.</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VE-40 (Vent RR x TV/Weight) x (PaCO2/40) at study hour 0, 48, 96, 168 if still intubated, in ascorbate infused patient compared to placebo</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA scores at hours 48, 96, 168</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascorbate level at hour 0, 48, 96, 168</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator Free Days to day 28</measure>
    <time_frame>Up to Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-free days at day 28</measure>
    <time_frame>Up to Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality to day 28</measure>
    <time_frame>Up to Day 28</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days at day 60</measure>
    <time_frame>Up to Day 60</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procalcitonin at study hour 0, 48, 96, 168</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Receptor for Advanced Glycation Endpoints at study hour 0, 48, 96, 168</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue factor pathway inhibitor at study hour 0, 48, 96, 168</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA Score Component at hours 48,96, 168: PaO2/FiO2</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA Score Components at hours 48,96, 168: SpO2/FiO2</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA Score Components at hours 48,96, 168: Platelets</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA Score Components at hours 48,96, 168: Total Bilirubin</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA Score Components at hours 48,96, 168: Vasopressor status</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA Score Components at hours 48,96, 168: GCS</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA Score Components at hours 48,96, 168: Creatinine or Urine Output</measure>
    <time_frame>Up to hour 168</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Acute Lung Injury</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Ascorbic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200mg/kg/day divided over 4 doses.  Administered every 6 hours for 96 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5% Dextrose in Water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50ml every 6 hours for 96 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <arm_group_label>Ascorbic Acid</arm_group_label>
    <other_name>Vitamin C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients must have suspected or proven infection, and meet 2 out of 4 of the criteria for
        Systemic Inflammatory Response (SIRS) due to infection, and be accompanied by at least 1
        criterion for sepsis-induced organ dysfunction, and meet all 5 criteria for Acute
        Respiratory Distress Syndrome (ARDS).

          1. Suspected or proven infection: (e.g., thorax, urinary tract, abdomen, skin, sinuses,
             central venous catheters, and central nervous system, see Appendix A).

          2. The presence of a systemic inflammatory response: Defined as: fever:  &gt;38ºC (any
             route) or hypothermia: &lt;36ºC (core temp only), tachycardia: heart rate &gt; 90 beats/min
             or receiving medications that slow heart rate or paced rhythm, leukocytosis:  &gt;12,000
             WBC/µL or leukopenia:  &lt;4,000 WBC/µL or &gt;10% band forms.  Respiratory rate &gt; 20
             breaths per minute or PaCO2 &lt; 32 or  invasive mechanical ventilation.

          3. The presence of sepsis-induced organ dysfunction: (any of the following thought to be
             due to infection)

               -  Sepsis-induced hypotension (systolic blood pressure (SBP) &lt; 90 mm Hg or an SBP
                  decrease &gt; 40 mm Hg unexplained by other causes or use of vasopressors for blood
                  pressure support (epinephrine, norepinephrine, dopamine =/&gt; 5mcg, phenylephrine,
                  vasopressin)

               -  Arterial hypoxemia (PaO2/FiO2 &lt; 300) or supplemental O2 &gt; 6LPM.

               -  Lactate &gt; upper limits of normal laboratory results

               -  Urine output &lt; 0.5 ml/kg/hour for &gt; two hours despite adequate fluid
                  resuscitation

               -  Platelet count &lt; 100,000 per mcL

               -  Coagulopathy (INR &gt; 1.5)

               -  Bilirubin &gt; 2 mg/dL

               -  Glasgow Coma Scale &lt; 11 or a positive CAM ICU score

          4. ARDS characterized by all the following criteria

               -  Lung injury of acute onset, within 1 week of an apparent clinical insult and
                  with progression of respiratory symptoms

               -  Bilateral opacities on chest imaging not explained by other pulmonary pathology
                  (e.g. pleural effusions, lung collapse, or nodules)

               -  Respiratory failure not explained by heart failure or volume overload

               -  Decreased arterial PaO2/FiO2 ratio ≤ 300 mm Hg

               -  Minimum PEEP of 5 cmH2O

        Exclusion Criteria:

          1. Known allergy to Vitamin C

          2. inability to obtain consent;

          3. age &lt; 18 years;

          4. more than 7 days since starting mechanical ventilation;

          5. more than 48 hrs since meeting ARDS criteria;

          6. patient or surrogate or physician not committed to full support (not excluded if
             patient would receive all supportive care except for cardiac resuscitation);

          7. pregnancy or breast feeding,

          8. moribund patient not expected to survive 24 hours;

          9. home mechanical ventilation (via tracheotomy or noninvasive) except for CPAP/BIPAP
             used only for sleep-disordered breathing;

         10. home O2, except for with CPAP/BIPAP

         11. BMI &gt; 40

         12. diffuse alveolar hemorrhage (vasculitis);

         13. interstitial lung disease requiring continuous home oxygen therapy;

         14. Active kidney stone

         15. primary care givers unwilling/unable to use ARDSnet 6 ml/kg ventilation protocol;

         16. Non English speaking;

         17. Ward of the state (inmate, other)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alpha B. Fowler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine DeWilde, RN</last_name>
    <phone>804-628-5710</phone>
    <email>dewildect@vcu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emory University and Grady Memorial Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Greg Martin, MD, MSc</last_name>
      <phone>404-616-0148</phone>
      <email>greg.martin@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Sevransky, MD, MHS</last_name>
      <phone>404-778-0599</phone>
      <email>jsevran@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Greg Martin, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan Sevransky, MD, MHS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Duncan Hite, MD</last_name>
      <phone>216-445-3098</phone>
      <email>hited@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Ferrari, RN</last_name>
      <phone>216-445-1939</phone>
      <email>ferrarm1@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Duncan Hite, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and The Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathon Truwit, MD</last_name>
      <email>jonathon.truwit@froedtert.com</email>
    </contact>
    <contact_backup>
      <last_name>Jeanette Graf</last_name>
      <phone>414-955-6987</phone>
      <email>jgraf@mcw.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathon Truwit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>March 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
